PPARG and metabolic disease: Previous studies indicated that supplementation with SCFAs effectively decreased the expressing level of peroxisome proliferator-activated receptor gamma (PPARγ) in mice, achieved the transformation from lipid synthesis to lipid oxidation, and alleviated the metabolic disorders induced by HFD [59].